May 13 (Reuters)-
Brightpath Biotherapeutics Co., Ltd.
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2021 Mar 31, 2020 Mar 31, 2022 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 2 mln 11 mln 2 mln
(-77.8 pct) (-92.7 pct) (-20.1 pct)
Operating loss 1.73 loss 1.83 loss 1.85
Recurring loss 1.74 loss 1.82 loss 1.85
Net loss 1.72 loss 1.86 loss 1.85
EPS loss 36.14 yen loss 44.20 yen loss 36.49 yen
Ann Div NIL NIL NIL
-Q2 Div NIL NIL NIL
-Q4 Div NIL NIL NIL
NOTE - Brightpath Biotherapeutics Co., Ltd..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4594.T